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Abstract A novel hexyl-substituted methylenecyclopropyl acet-
yl-CoA was tested as an enzyme-specific acyl-CoA dehydrogen-
ase inhibitor. Its CoA ester generated in situ from the carboxylic
acid and CoASH, displayed marked differences in inhibition
specificity as compared to methylenecyclopropyl acetyl-CoA,
consistent with the substrate specificities of the target enzymes.
Thus methylenecyclopropyl acetyl-CoA inactivated short-chain-
specific acyl-CoA dehydrogenase rapidly, medium-chain-specific
acyl-CoA dehydrogenase much more slowly and had no effect on
long-chain- or very long-chain-specific acyl-CoA dehydro-
genases. The hexyl-substituent on the methylenecyclopropyl ring
gave an inhibitor which rapidly inactivated MCAD and LCAD
whilst VLCAD was inhibited more slowly and SCAD was
essentially unaffected. In some cases (e.g. SCAD and MCPA-
CoA) inhibition was accompanied by flavin bleaching. In other
cases (e.g. LCAD and C6MCPA) less pronounced bleaching
suggests a different chemistry of inhibition.
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Key words: Acyl-CoA dehydrogenase; Covalent inhibitor;
Alkyl-substituted methylenecyclopropane acetyl-CoA;
Flavin alkylation; Active-site-directed inhibitor
1. Introduction
Acyl-CoA dehydrogenases are mitochondrial £avoproteins
which catalyse the oxidation of saturated acyl-CoA esters
to give the corresponding 2,3-trans-unsaturated compounds
[1]. Six such enzymes have been described in mammals [2,3] ;
short-chain-speci¢c (SCAD), medium-chain-speci¢c (MCAD),
long-chain-speci¢c (LCAD) and very long-chain-speci¢c acyl-
CoA dehydrogenase (VLCAD) have overlapping substrate
speci¢city pro¢les and catalyse the ¢rst of the four steps seri-
ally repeated in the L-oxidation spiral of fatty acid oxidation
[1,4]. Isovaleryl-CoA dehydrogenase (IVD) and 2-methyl-
branched-chain acyl-CoA dehydrogenase (2MeBCD) catalyse
the oxidation of carbon skeletons from branched chain amino
acid degradation [5].
Methylenecyclopropyl acetyl-CoA (MCPA-CoA), a metab-
olite of the unusual amino acid hypoglycin, is the causative
agent of Jamaican vomiting sickness [6]. Both in vitro and in
vivo, MCPA-CoA inhibits SCAD, MCAD, IVD and
2MeBCD, whilst LCAD is una¡ected [7^11]. There is also
one report of MCAD being una¡ected by MCPA-CoA [12].
MCPA-CoA, a ‘suicide’ or mechanism-based inhibitor [7],
causes irreversible inhibition through covalent modi¢cation
of the £avin prosthetic group [7,13]. The lower homologue,
methylenecyclopropyl formyl-CoA (MCPF-CoA), exhibits a
rather di¡erent target speci¢city, giving potent inhibition of
2MeBCD and IVD whilst SCAD is rather weakly inhibited
and MCAD and LCAD are una¡ected [14,15]. Inhibition by
this compound is irreversible but the mechanism of action is
unknown [14,15]. Recently it was reported that spiropentane
acetyl-CoA (SPA-CoA) preferentially inhibited octanoyl-CoA
dehydrogenase activity in liver homogenates [16]. The
branched-chain acyl-CoA dehydrogenase activities appeared
to be una¡ected by SPA-CoA [16].
The di¡erent e¡ects of MCPA-CoA, MCPF-CoA and SPA-
CoA indicate the potential for targeting inhibitors towards
speci¢c acyl-CoA dehydrogenases. We have used a hexyl-sub-
stituted derivative of MCPA to investigate this possibility fur-
ther and now report on the e¡ects of this novel inhibitor on
the catalytic activity and absorption spectra of SCAD,
MCAD, LCAD and VLCAD.
2. Materials and methods
2.1. Chemicals
Coenzyme A (trilithium salt), Sephadex G-200 and monoQ columns
were from Pharmacia. ATP was from Boehringer Mannheim. Acyl-
CoA esters were from Sigma. Hydroxyapatite was from Bio-Rad.
Cellulose powder (CC31 microgranular) was from Whatman Lab
Sales. All other reagents were of the highest grade commercially avail-
able.
The methylenecyclopropane carboxylic acids used in this study,
MCPA and C6MCPA, were a generous gift from Professor Charles
Stirling, Department of Chemistry, University of She⁄eld. Methyle-
necyclopropane synthesized by Koster’s procedure [17] was lithiated
by treating with butyl lithium in tetrahydrofuran [18] and subse-
quently alkylated [19]. The alkyl methylenecyclopropane was again
lithiated and then reacted with ethylene oxide. The resulting alcohol
was oxidized with chromium trioxide [20] to yield the desired carbox-
ylic acid. Proton NMR showed that the acids were not 100% pure,
but, in view of the subsequent procedures to be used and the insta-
bility of the compounds, they were used without further puri¢cation.
2.2. Enzymes
Medium-chain-length-speci¢c acyl-CoA synthetase was puri¢ed
from pig liver mitochondria [21]. SCAD, MCAD and LCAD were
puri¢ed from bovine liver. SCAD, puri¢ed as described previously
[22] was prepared in yellow (CoA persulphide-free) and green (CoA
persulphide-liganded) forms [23,24]. The side fraction described in
[22], containing MCAD and LCAD, was used for their further puri-
¢cation. MCAD and LCAD were separated on a hydroxyapatite-cel-
lulose column [25]. MCAD was further puri¢ed by gel-¢ltration on a
Sephadex G-200 column (100U1.5 cm) equilibrated with KH2PO4/
K2HPO4 bu¡er (50 mM, pH 7.6) containing EDTA (0.3 mM) and
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eluted at approximately 20 ml/h with the same bu¡er. LCAD was
further puri¢ed by fplc anion-exchange on monoQ (5/5 column) equi-
librated with HEPES bu¡er (20 mM, pH 7.5). LCAD was eluted with
a KCl gradient (two column volumes at 0 mM KCl ,step to ¢ve
column volumes at 200 mM KCl followed by a linear gradient
of 200 mM to 500 mM KCl over 30 column volumes; £ow
rate = 1 ml/min). During puri¢cation acyl-CoA dehydrogenase activity
was monitored by assaying with butyryl-CoA, lauroyl-CoA and
3-phenylpropionyl-CoA, the latter being a speci¢c substrate for
MCAD. SCAD preparations displayed no activity with lauroyl-CoA
or 3-phenylpropionyl-CoA indicating them to be free of MCAD and
LCAD. LCAD preparations displayed no activity with 3-phenyl-
propionyl-CoA indicating them to be free of MCAD. VLCAD was
a generous gift from Professor T. Hashimoto [3].
2.3. Enzyme assays
Acyl-CoA synthetase was assayed by following the decrease in free
CoASH on incorporation into acyl-CoA thioesters [26]. Reaction mix-
tures (1 ml) contained: ATP (4 mM), MgCl2 (4 mM), CoASH (tri-
lithium salt, 0.4 mM), fatty acid substrate (0.1^1 mM) and acyl-CoA
synthetase in KH2PO4/K2HPO4 bu¡er (100 mM, pH 7.1). Acyl-CoA
dehydrogenases were assayed at 25‡C using a dye-linked system [22].
Assays (1 ml) contained: KH2PO4/K2HPO4 bu¡er (100 mM, pH 7.1),
dichlorophenolindophenol (0.0001% (w/v)), N-ethylmaleimide (200
WM), acyl-CoA substrate (50 WM), enzyme and phenazine ethosul-
phate (0.6 mM for SCAD assays, 6 mM for MCAD assays, 3 mM
for LCAD and VLCAD assays). Assays were initiated by phenazine
ethosulphate addition exactly 2 min after addition of the enzyme.
2.4. Inhibition incubations
The CoA thioesters of MCPA and C6MCPA were generated in situ
by using pig liver mitochondrial acyl-CoA synthetase. The complete
system consisted of an acyl-CoA synthetase reaction mixture to which
the acyl-CoA dehydrogenase of interest was added (usually 1 WM by
£avin absorbance). The carboxylic acid substrate was the MCPA
compound to be studied. Samples were periodically removed and
assayed for acyl-CoA dehydrogenase activity (10 Wl samples) and
for CoASH consumption (= thioester synthesis) (150 Wl samples) ex-
actly as in acyl-CoA synthetase assays [26]. The amount of acyl-CoA
synthetase used was adjusted according to which MCPA compound
was being used so that the rate of thioester synthesis in the incubation
mixture was approximately 80 nmol/h/ml.
2.5. Absorption spectra
For all measurements of spectra the test cuvette contained the
standard acyl-CoA synthetase reaction mixture plus acyl-CoA dehy-
drogenase. The reference cuvette contained only the acyl-CoA synthe-
tase reaction mixture. Inhibition was initiated by addition of the ap-
propriate MCPA compound. Spectra were recorded at 10 nm/s in a
Cary 219 UV/vis spectrophotometer at room temperature. In some
experiments during incubation with the inhibitors, the 30 s scan time
inevitably entails a distortion of the true instantaneous spectrum. This
e¡ect should be slight, however, since incubation times were 1^2 h.
Aliquots were removed for assay of acyl-CoA dehydrogenase activity
as described above.
3. Results and discussion
3.1. E¡ects of methylenecyclopropyl compounds on activity
The structures of the compounds used in this study are
shown in Fig. 1. The hexyl-substituent on C6MCPA can be
considered to give a compound with a C10 ‘backbone’ whilst
by the same argument MCPA can be considered to have a C4
‘backbone’. The progressive inhibitory e¡ects on puri¢ed
preparations of SCAD, MCAD, LCAD and VLCAD of
MCPA-CoA and C6MCPA-CoA (both generated in situ using
acyl-CoA synthetase) are shown in Fig. 2. In no case was
inhibition observed in the absence of ATP and CoASH or
when MCPA or C6MCPA were omitted from an otherwise
complete reaction mixture. This indicates that the CoA thio-
esters of these compounds are the active species. Inhibition
was always irreversible, no activity being regained on exten-
sive dialysis against potassium phosphate bu¡er (100 mM, pH
7.1). The two inhibitors display very di¡erent target speci¢city
with respect to the enzymes they inhibit ; these di¡erences are
consistent with the substrate speci¢cities of the target en-
zymes. The main target of MCPA-CoA was SCAD (using
yellow enzyme free of CoA persulphide). By comparison,
MCAD was much more slowly inhibited whilst LCAD and
VLCAD were una¡ected. These data are in broad agreement
with earlier reports that MCPA-CoA inhibits SCAD and
MCAD but not LCAD [10,11]. However, whilst Tanaka’s
laboratory, working with puri¢ed rat liver enzymes, reported
that MCAD was inhibited slightly faster than SCAD [10] it
was shown by Tserng et al. [16] that MCPA-CoA inhibits
SCAD more rapidly than MCAD in bovine liver homoge-
nates. The relatively slower inhibition of MCAD observed
with the bovine enzymes presumably re£ects subtle di¡erences
in the substrate speci¢city of the bovine and rat enzymes.
Bovine SCAD is active with C4 to C8 (optimum C4) acyl-
CoA esters [2,25,27] and consequently MCPA-CoA is of the
correct ‘size’ to be acted on by this enzyme. Bovine MCAD is
active with C4 to C18 (optimum C6 to C8) acyl-CoA esters
[2,25,27] and so can act slowly on MCPA-CoA. Bovine
LCAD is active with C6 to C20 (optimum C10 and C12)
acyl-CoA esters [2,21,23] and rat VLCAD is active with C10
to C24 (optimum C16 and C18) acyl-CoA esters [3] and con-
sequently MCPA-CoA is of too short a ‘chain-length’ to be
acted on by these latter two enzymes.
Green SCAD (i.e. enzyme liganded with CoA persulphide
[24]) exhibits a very di¡erent time-course of inhibition from
yellow (CoA persulphide-free) SCAD (Fig. 2A). The signi¢-
cant lag period before any inhibition is observed with green
SCAD presumably re£ects the need for MCPA-CoA to dis-
place CoA persulphide from the enzyme active site before
inhibition can occur; similarly, normal catalytic assays of
green SCAD display a signi¢cant lag (during which time bu-
tyryl-CoA displaces CoA persulphide) before maximum activ-
ity is observed [23]. In the present work samples were incu-
bated with 50 WM butyryl-CoA and 200 WM N-ethylmaleimide
for exactly 2 min before initiating activity assays by addition
of PES. Reaction traces did not display any lag, indicating
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Fig. 1. Structure of the free acid forms of MCPA and C6MCPA.
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that the CoA persulphide had been completely displaced from
the enzyme active site (by butyryl-CoA and/or by reaction
with N-ethylmaleimide). Protection against inhibition by
CoA persulphide is a further line of evidence that MCPA-
CoA is acting at the active site of SCAD.
C6MCPA-CoA rapidly inhibited both MCAD and LCAD
whilst VLCAD was inhibited more slowly and only after a
distinct lag period (Fig. 2B). By contrast, SCAD was essen-
tially una¡ected. The C10 ‘backbone’ C6MCPA-CoA is too
long to be acted on by SCAD and is only just long enough
to be acted on by VLCAD. The C10 ‘backbone’ of C6MCPA-
CoA is, however, of a suitable ‘chain-length’ for it to be acted
on rapidly by both MCAD and LCAD. The lag period before
VLCAD is inhibited by C6MCPA-CoA is consistent with a
low a⁄nity of VLCAD for this inhibitor as compared to
MCAD or LCAD. Since C6MCPA-CoA was generated in
situ from C6MCPA the concentration of the inhibitor in-
creased linearly with time throughout the inhibition incuba-
tion. Thus the lag in the inhibition of VLCAD results from
the need for a su⁄ciently high concentration of C6MCPA-
CoA to be generated before inhibition is observed. In con-
trast, inhibition of MCAD and LCAD was observed within
5 min, indicating a much lower concentration of C6MCPA-
CoA is required to inhibit these enzymes. When the amount
of acyl-CoA synthetase (and hence rate of thioester synthesis)
was reduced in inhibition incubations of C6MCPA with
MCAD and LCAD, a lag similar to that seen with VLCAD
and consistent with the above argument was observed (data
not shown).
3.2. E¡ect on absorption spectra
The e¡ects of MCPA-CoA and C6MCPA-CoA on the ab-
sorption spectra of the acyl-CoA dehydrogenases were exam-
ined in order to gain insight into the nature of the inhibition,
i.e. whether inhibition was due to modi¢cation of the £avin
prosthetic group and/or the enzyme protein itself. The en-
zyme-inhibitor combinations examined were SCAD/MCPA-
CoA, MCAD/C6MCPA-CoA, and LCAD/C6MCPA-CoA,
i.e. each enzyme was incubated with its ‘optimum’ inhibitor.
Inhibition of SCAD by MCPA-CoA resulted in bleaching of
the characteristic £avin absorption spectrum (Fig. 3A) as has
been described for Megasphaera elsdenii butyryl-CoA dehy-
drogenase [28] and porcine kidney MCAD [7], for which it
has been shown that inhibition is due to modi¢cation of the
FAD prosthetic group [7]. Inhibition of MCAD by C6MCPA-
CoA also resulted in bleaching of the £avin (Fig. 3B) suggest-
ing that in this case inhibition is also due to modi¢cation of
the prosthetic group.
By contrast, inhibition of LCAD by C6MCPA-CoA was
accompanied by only slight bleaching of the £avin (Fig.
3C). In the representative experiment shown (Fig. 3C) after
60 min incubation activity had been inhibited 96% whereas
the absorbance at 448 nm had decreased only by 32%. The
£avin remained capable of reduction by Na2S2O4. Lack of
£avin bleaching is characteristic of inhibitors that act via
modi¢cation of the enzyme protein [29^31], suggesting that
in this case C6MCPA-CoA causes inhibition mainly by mod-
i¢cation of the LCAD protein itself.
The observation that C6MCPA-CoA inhibits both MCAD
and LCAD but apparently in di¡erent ways is noteworthy. In
MCAD in which inhibition by C6MCPA-CoA appears to be
due to £avin modi¢cation the K-proton-abstracting base is
Glu-376 [31,32]. In SCAD, for which it is well documented
that inhibition by MCPA-CoA is due to modi¢cation of the
£avin [7,13,33], this residue is conserved and is thought also to
act as the proton-abstracting base [33]. However, in LCAD
this residue is replaced by glycine and another residue, Glu-
261 (which corresponds to Glu-255 in the MCAD sequence)
acts as the K-proton-abstracting base [34]. Thus, di¡erences of
the detailed topology of the active sites of MCAD and LCAD
may explain the apparently di¡erent mechanisms of inhibition
of these two enzymes by the same inhibitor. In this connection
it is noteworthy that recent work in Ghisla’s laboratory [35]
shows that the di¡erent position of the catalytic base in
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Fig. 2. E¡ect of MCPA-CoA and C6MCPA-CoA (generated in situ)
on the activity of puri¢ed SCAD, MCAD, LCAD and VLCAD. In-
cubations contained 1 WM acyl-CoA dehydrogenase, 0.4 mM
CoASH, 4 mM ATP, 4 mM MgCl2, MCPA (200 WM) or C6MCPA
(100 WM) and porcine acyl-CoA synthetase (100 Wg) in potassium
phosphate bu¡er (100 mM, pH 7.1). A: b, SCAD (yellow)/MCPA;
a, SCAD (green)/MCPA; R, MCAD/MCPA. B: F, MCAD/
C6MCPA; R, LCAD/C6MCPA; O, VLCAD/C6MCPA. In each
case data are from a single experiment which is representative of
three independent experiments.
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MCAD and LCAD is important in determining the acyl-
chain-length speci¢city of these enzymes, i.e. the position of
the catalytic base profoundly a¡ects the topology of the acyl-
CoA binding site.
The present studies clearly illustrate the potential for de-
signing enzyme-speci¢c acyl-CoA dehydrogenase inhibitors.
In view of the overlapping acyl-chain-length speci¢cities of
the acyl-CoA dehydrogenases it is not surprising that
C6MCPA-CoA did not speci¢cally inhibit just one enzyme.
The compound 3-phenylpropionyl-CoA is a speci¢c substrate
for MCAD. Thus it is possible that substitution of the meth-
ylenecyclopropyl ring with an a benzyl group may produce an
MCAD-speci¢c inhibitor.
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